Non-del(5q) transfusion-dependent low/int-1 MDS patients achieve an erythroid response with lenalidomide in 25-30% of cases. Addition of erythropoiesis-stimulating agent could improve the erythroid response rate. The impact of recurrent somatic mutations identified in the diseased clone on response to lenalidomide and the drug effects on clonal evolution remain unknown. 
Abstract
Non-del(5q) transfusion-dependent low/int-1 MDS patients achieve an erythroid response with lenalidomide in 25-30% of cases. Addition of erythropoiesis-stimulating agent could improve the erythroid response rate. The impact of recurrent somatic mutations identified in the diseased clone on response to lenalidomide and the drug effects on clonal evolution remain unknown. We investigated recurrent mutations by next generation sequencing in 94 non-del(5q) MDS patients randomized in the GFM-Len-Epo2008 clinical trial to lenalidomide or lenalidomide + EPO. Clonal evolution was analyzed after 4 cycles of treatment in 42 cases, and re-analyzed at later time points in 18 cases. The fate of clonal architecture of single CD34 +
CD38
-hematopoietic stem cells was also determined in 5 cases. Four genes had a mutation frequency over 10%: SF3B1 (74.5%), TET2 (45.7%), DNMT3A (20.2%) and ASXL1 Lenalidomide is another compound approved for treating anemia in lower risk MDS patients with deletion of the long arm of chromosome 5 (del[5q] ), where it yields red blood cell (RBC) transfusion independence (RBC-TI) in 60-75 % of cases, and a complete or partial cytogenetic response in 40 to 60 % of them. 1, 2, 3, 4, 5 In this setting, the molecular target of lenalidomide was shown to be Cereblon, a protein that is part of an E3 ubiquitin ligase complex, Cereblon-CUL4-ROC1. Lenalidomide activates this E3 ligase that, in turn, ubiquitinates and degrades casein kinase 1A, encoded by the CSNK1A1 gene located in the 5q
commonly deleted region, which may cause cell death.
6
Lenalidomide also yields erythroid response (HI-E) and RBC-TI in 20-30% of MDS patients without del(5q), who are resistant to ESA. 7, 8 In this context, the addition of high doses of epoetin was suggested to increase the haematological response to lenalidomide. 9,10 Predictive biomarkers of response are needed to guide the use of lenalidomide, with or without ESA, in these patients and recurrent somatic mutations could be such molecular predictors. The present study investigated mutations in 26 selected genes [11] [12] [13] For personal use only. on October 4, 2017 . by guest www.bloodjournal.org From
Patients and methods

Patient characteristics
International Prognostic Scoring System (IPSS) low and int-1 risk non del(5q) MDS (n=131) were enrolled in the GFM-Len-Epo-2008 clinical trial of the Groupe Francophone des Myélodysplasies (registered at clinicaltrials.gov, NCT01718379) after specific informed consent according to the recommendations of the local ethics committee. All the studied patients had failed to respond to ESA (used for at least 12 consecutive weeks at a minimum dosage of 60 000 UI epoetin or 250 µg darbepoetin per week) or had relapsed after initial response to ESA, and were RBC transfusion dependent of at least 4 RBC units over the last 8 weeks. These patients received lenalidomide at a dose of 10 mg/day for 21 days every 28 days, either alone or combined with epoetin β 60 000 UI/week (EPO). Transfusion dependency and hematological improvement of the erythroid lineage (HI-E), defined according to International Working Group (IWG) 2006 criteria, were evaluated after the fourth cycle in 99 patients.
14 Treatments were continued in responders until relapse. BM aspirates were collected in 94 patients (47 in each arm) at inclusion, in 42/94 patients after 4
cycles of treatment and in 18 patients during later follow-up (between 12 -26 months) and processed for biological studies. No patient was excluded on the basis of initial clinical and biological characteristics (Tables 1 and S1).
(NGS) assay using the Ion AmpliSeq™ library kit2 384 (Life Technologies, Chicago, IL).
Multiplex PCR amplifications (233 primer pairs) were performed from 2x10 ng of genomic DNA. After amplification, barcodes and adaptors were added to amplicons by ligation.
Products were subjected to a selective purification on AMPure beads (Life Technologies).
Emulsion PCR (emPCR) was performed using the OneTouchV2 (Life Technologies) instrument. Sequencing was performed on Ion PGM™ (Life Technologies) onto the 318 V2 chip (15 samples per chip). All the samples were also screened for ASXL1 (including c.1934dupG; p.G646WfsX12) and SRSF2 mutations by Sanger sequencing. JAK2, NPM1, and FLT3-ITD mutations were also investigated by qPCR and fluorescent PCR.
Bioinformatic analysis
Base calls were generated by the Torrent Browser software using the included variant caller with an additional plug-in (Life Technologies). The .bam and .vcf files were used for further analysis. The .vcf files were annotated with the Ion reporter software (Life Technologies) and processed for a second analysis of the indexed files using the NextGENe software (Softgenetics, State College, PA). Results were compared to select abnormalities that will be further considered. For each mutation, depth at the variant position (number of mutated reads and unmutated reads) was considered to calculate variant allele frequency (VAF), which is the proportion of mutated reads among total reads and its 95% confidence interval (95% CI). For each patient, pairwise comparisons between the variant allele frequencies of mutations were performed using Fisher's exact test and mutations with the significantly highest variant allele frequencies were considered as major mutations. For patients with one unique genetic event, the isolated mutation was considered as a major mutation. To assess clonal evolution after treatment, for each patient, variant allele frequencies of a given mutation were compared between two consecutive time points of the follow-up period using the Fisher's exact test. P For personal use only. on October 4, 2017 . by guest www.bloodjournal.org From values < 0.05 were considered as significant and analyses were performed using Statsmodels package (Python software, Beaverton, OR).
Single cell cloning and genotyping
Cryopreserved BM mononuclear cells were thawed at 37°C in RPMI-1640 were presented by the Odds ratio (OR) and its 95% CI. The four most common genes mutated in >10% patients were included in a multivariate logistic model adjusting for treatment arm to assess independent prognostic factors. Interactions between each of the four mutations and treatment arm were assessed using Gail and Simon's heterogeneity test.
15 All statistical tests were considered significant for P values < 0.05. Analyses were performed using the SAS 9.3 software (SAS Inc, Cary, NC), R version 3.0.2 (The R Foundation for Statistical Computing) and Python Statsmodels package (Python Software foundation).
Results
Baseline characteristics including mutational profile and response to treatment
Twenty six genes recurrently mutated in MDS were sequenced in the 94 BM samples obtained before treatment (Table S2) P=0.227) mutations (Fig. 2B) .
DNMT3A mutations predict better response
Of the 94 patients, 47 were randomized to lenalidomide arm and 47 to lenalidomide+EPO arm. Forty patients achieved HI-E after 4 cycles of treatment and 54 patients were non- 
Lenalidomide often decreases the size of the dominant subclone
Using NGS, we sequentially analyzed the clonal architecture of 42 BM samples. Before treatment, all these samples harbored a dominant subclone containing 1 to 4 different mutations, with variation in mutated genes between patients. We also identified minor subclones in 29 cases. After 4 cycles of treatment, 20 of these patients were classified as responders and 22 as non-responders. In 25 cases, we observed a decrease in the size of the dominant subclone, indicated by a decrease in SF3B1, DNMT3A or TET2 mutated allele burden as compared to pre-treatment sample. Fifteen/25 (60%) patients were responders. In the 17 other cases, the variant allele frequency of major mutations remained stable or increased and only 5/17 (29%) were responders (Table S5; Fig. 3 & S2) . Based on these For personal use only. on October 4, 2017 . by guest www.bloodjournal.org From numbers, there was a trend to associate treatment response with decrease in the size of the dominant clone (chi-squared; P=0.066). These results are summarized in Fig. 4A showing the evolution of variant allele frequencies before and after 4 cycles of treatment. Furthermore, treatment-induced decrease of variant allele frequencies was more significant in responders compared to non-responders (Mann Whitney test; P<0.001; Fig. 4B ). This suggests that response to treatment is associated with changes of dominant clone size. Strikingly, in 9 cases (UPN 17, 24, 29, 40, 61, 69, 91, 96, 110) , major DNMT3A, SF3B1, TET2 or ASXL1 mutation remained stable while other mutations of the dominant clone decreased. Only 2/9 were responders. By contrast, 12/16 patients with a significant decrease of all the mutations that define the dominant clone were responders ( Fig. 3 & S2 ; Table S5 ). The evolution of minor subclones was also examined. In 15 cases, at least one of the identified minor mutations decreased while in 14 cases, the variant allele frequencies of these minor mutations increased or remained stable. There was no correlation between response to treatment and evolution of minor subclones ( Fig. 3 & S2 ; Table S5 ). We also evaluated the impact of EPO on clonal evolution in 22 patients treated by lenalidomide+EPO versus 20 patients treated by lenalidomide alone. Addition of EPO did not change the proportion of patients demonstrating a decrease of major or minor mutations compared to lenalidomide alone.
Altogether, these results show that, after 4 cycles of treatment by lenalidomide ± EPO, the size of the dominant clone decreased more importantly in responders than in non-responders, and that clonal dynamics was not influenced by the addition of EPO.
Clonal architecture of CD34 +
CD38
-hematopoietic stem cell compartment
To further assess the impact of treatment on clonal evolution, we reconstructed clonal architecture of hematopoietic stem cell compartment at single cell level. We sorted BM CD34 + CD38 -HSC before and after 4 cycles of treatment and co-cultured them for 6 weeks on murine MS-5 cell line. Single cell-derived colonies were harvested and genotyped using mutation-specific PCR and Sanger sequencing, in a search for each mutation initially identified by NGS in BM mononuclear cells (Fig. S1A) . (Fig. S1B) . Importantly, the percentage of colonies screened positive for a given variant was consistent with the variant allele frequency determined by NGS in BM mononuclear cells (Fig. S1C) , suggesting that in vitro culture might not introduce any bias in clonal representation.
Genotyping of single CD34 + CD38 -cells identified a dominant clone and one or several minor subclones generated by the occurrence of additional mutations in a cell of the dominant clone or, in one case, in an independent clone. In all 5 tested patients, at least two or three mutations were found in more than 50% of single CD34 + CD38 --derived colonies, suggesting the early amplification of a dominant clone at the HSC level (Fig. 5) .
In a first patient (UPN 054), DNMT3A and SF3B1 mutations were initially identified in all studied single cell-derived colonies. This patient responded to lenalidomide and response was associated with disappearance of SF3B1/DNMT3A double-mutated cells, remaining cells being either devoid of driver mutation or mutated only for DNMT3A. In this patient, lenalidomide appeared to specifically decrease the competitiveness of the most mutated cells (Fig. 5) . In a second patient (UPN 091), a DNMT3A mutation was identified in 74% of the colonies, including 8% with DNMT3A alone, 58% with DNMT3A and SF3B1 exon15 mutations and 8% with DNMT3A and SF3B1 exon14 mutations, suggesting that DNMT3A mutation preceded the acquisition of two distinct SF3B1 mutations, defining 2 branched subclones. Response to lenalidomide plus EPO observed in this patient was associated with a decrease in the size of the dominant clone (DNMT3A/SF3B1exon15) together with the expansion of the initially smaller clone (DNMT3A/SF3B1exon14) (Fig. 5) . In a third one
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From (UPN 129), 84% of the single-cell derived colonies initially contained a TET2 mutation and 23% of them contained an additional SRSF2 mutation. Response to lenalidomide plus EPO obtained in this patient was not associated with any significant change in clonal architecture (Fig. 5) . In a fourth patient (UPN 030), SF3B1 mutation was found alone in 8% of the colonies and combined with a TET2 mutation in 85% of them, suggesting that SF3B1 mutation preceded the occurrence of TET2 mutation. A unique ZRSR2 mutation was detected in 8% of the cells, suggesting an independent clone. Although this patient did not respond to lenalidomide plus EPO, the most mutated SF3B1/TET2 clone decreased. A subclone with only SF3B1 or cells with no mutation in these 3 genes expanded and the isolated clone with a single ZRSR2 mutation disappeared. In a last patient (UPN 073), before treatment, 98% of the cells had mutations in TET2, ASXL1 and SRSF2 genes and an additional NRAS mutation was detected in only 2% of the cells, defining a minor clone. This patient failed to respond to lenalidomide plus EPO, and failure was associated with the expansion of the minor, NRASmutated clone to 16% (Fig. 5) . Finally, analysis of clonal architecture at the single cell level helped discriminating between dominant and founding clones. In UPN 091, DNMT3A appeared as a founding mutation preceding the onset of two different SF3B1 mutations in two distinct clones. In UPN 030 and 054, post-treatment experiments demonstrated that the double mutated clone decreased to the benefit of a clone with a single mutation.
Altogether, these observations indicate that 4 cycles of lenalidomide, with or without EPO, induce changes in the size and distribution of clones in the CD34 + CD38
-cell compartment, but that these changes do not accurately reflect the clinical response to the drug.
Long term follow-up
To determine whether lenalidomide ± EPO treatment had a reproducible impact on the mutated allele burden at later time points, we repeated targeted sequencing of BM For personal use only. on October 4, 2017. by guest www.bloodjournal.org From mononuclear cell samples collected after 5 to 28 cycles of treatment from 18 patients ( Table   2 ; Fig. 6 & Fig. S3 ). Four of them (UPN 130, 124, 91, 85) were still responders, after 10, 19, 22 and 23 months of treatment, respectively, 12 had relapsed, and 2 evolved to AML 9 and 15 months after inclusion.
Among the 4 still responding patients, one (UPN 085) had a stable dominant clone. In UPN 091, the size of the initially dominant clone (DNMT3A/SF3B1ex15) had decreased at the expense of the initially smaller subclone (DNMT3A/SF3B1ex14) and in UPN 124, dominant (SF3B1) and minor (TET2 and EZH2) mutations had decreased. In UPN 130, dominant SF3B1 mutation had re-increased while the two minor TET2 and KIT mutants remained poorly detectable (Fig. 6 & S3) .
In 12 out of 14 patients who relapsed or transformed, the dominant clone re-expanded, while it remained stable in UPN 077 and UPN 019 compared to inclusion. In one case (UPN 098), AML transformation at 15 months was associated with the sudden acquisition of an EZH2 mutation in the dominant SF3B1/DNMT3A/TET2 clone whose size had significantly decreased at 11 months (Fig. 6) . In 4 other cases, minor subclones defined by mutations in DNMT3A (UPN 013), DNMT3A and ASXL1 (UPN 033), TET2 (UPN 076), or JAK2 (UPN 110) increased concomitantly to the loss of treatment efficacy ( Fig. 6 & S3 ; Table 2 ).
Altogether, these results indicate that, although response to lenalidomide is often associated with a reduction in the size of the dominant subclone, it neither eradicates this clone nor prevents its re-expansion, sometimes associated with the emergence of minor mutations leading to loss of efficacy or AML transformation.
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Discussion
The current study indicates that the presence of a DNMT3A mutation could be predictive of a better response of non-del(5q) lower risk MDS to treatment. Most importantly, exploration of clonal evolution under lenalidomide or lenalidomide + EPO supports that therapeutic response is associated in 15/20 patients (75%) with a decrease in the size of the dominant clone, which re-expands upon relapse without being overtaken by an initially minor clone.
Some recurrent somatic mutations have an influence on overall survival in MDS, ASXL1 or DNMT3A mutations being linked to a poorer prognosis and SF3B1 mutations to a better outcome. [17] [18] [19] [20] The prognostic value of specific mutations may however vary depending on treatment administered. For example, while TET2 mutations has an overall "neutral" Figure 5 ). In addition, lenalidomide could theoretically promote the emergence of one or several subclones that carry a distinct pattern of mutations, which we did not observe in this series. In some cases in which the size of the dominant subclone had decreased, one major mutation could remain stable or increased. This suggests that lenalidomide might increase the fitness of a less mutated subclone that, in many cases may be the founding clone (UPN 030 & 129) . Finally, the decrease in the size of the dominant subclone could reflect a treatment-induced change in the proportion of myeloid versus lymphoid cells in the bone marrow mononuclear cell fraction. (UPN 030) . By contrast, the evolution of minor clones was not correlated with response to treatment. Long-term follow-up showed that the loss of treatment efficacy was associated with the re-increase of the dominant clone in the majority of cases, but limited expansion of an initially minor clone remained an option. Differences in the evolution of subclones under treatment may depend on the combination of mutations.
Alternatively, these mutations could occur in subsets of HSC with distinct properties to aging and drug sensitivity. 39, 40 In conclusion, our results show that lenalidomide response is usually associated with a decrease in the size of the dominant subclone and limited changes in the size of minor subclones. When the disease escapes lenalidomide activity or progresses to acute leukemia, the dominant subclone re-expands. Further investigation will indicate if lenalidomide eradicates part of the cells of the dominant subclone or decreases their competitiveness, which will be needed to understand how these cells escape lenalidomide activity and to optimize the clinical use of this drug. Table 2 : Long-term clonal evolution upon lenalidomide treatment in low/int-1 myelodysplastic syndromes. Targeted sequencing was performed before treatment and after more than 5 cycles of treatment in 18 patients. Major mutations are indicated in bold. For the last follow-up, number of treatment cycles (c) is indicated. Based on this statistical analysis, evolution of major and minor mutations is expressed as increase, decrease or stability. When major mutations initially decreased after 4 cycles of treatment and increased during long term follow-up, the evolution of major mutations is indicated as "re- e  2  3  c  1  9  r  e  -i  n  c  r  e  a  s  e  i  n  c  r  e  a  s  e   D  N  M  T  3  A   l  o  s  s  o  f  e  f  f  i  c  a  c  y  3 Radar plots of the variant allele frequencies at inclusion and after 4 cycles of treatment.
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